CLAIMS

1. A conjugate comprising Formula I:

T-L-X

wherein T is a SST2R targeting ligand, wherein the SST2R targeting ligand is Tyr^3-octreotide (TOC);
L is a linker, wherein L is PEG_n, and
X is a chelator, wherein the chelator is 1,4,7,10-tetraazacyclododecane-7-acetamide-1,4,10-triacetic acid (PSC),
for therapeutic treatment or medical imaging of cancer.

2. The conjugate of claim 1, wherein the conjugate is labeled with a radionuclide, and wherein the radionuclide is Pb-203 used for medical imaging of cancer.

3. The conjugate of claim 1, wherein the conjugate is labeled with a radionuclide, and wherein the radionuclide is Pb-212 used for treatment of cancer.

4. The conjugate of any one of the above claims, wherein n is 1-4.

5. The conjugate of claim 4 wherein n is 2 or 4.

6. Use of the conjugate of claim 1 in the manufacture of a medicament for the treatment of cancer.

7. The use of claim 6, wherein the conjugate is to be administered with an anti-cancer composition.